# EDGAR Filing Document

**Accession Number:** 0001888886
**File Stem:** 0001104659-25-062576
**Filing Date:** 2025-6
**Character Count:** 7480
**Document Hash:** 5a37daaf55ca24466f3b7a32d7aef546
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-062576.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001104659-25-062576

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250623

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Structure Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001888886
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981480821
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41608
- **FILM NUMBER:** 251073807

**BUSINESS ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD SUITE 223
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (628) 229-9277

**MAIL ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD SUITE 223
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ShouTi Inc.
- **DATE OF NAME CHANGE:** 20211019

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 23, 2025**

**Structure Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-41608** | **98-1480821** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **601 Gateway Blvd.** **, Suite 900**<br> **South San Francisco** **, California** | **94080** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(Registrant's telephone number, including area code): (650) 457-1978**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Name Of Each <br> Exchange<br> **Trading Symbol(s)** | **On Which<br> Registered** |
| American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share | GPCR | Nasdaq Global Market |
| Ordinary shares, par value $0.0001 per share\* |  | Nasdaq Global Market\* |

---

\* Not for trading, but only in connection with the registration of the American Depositary Shares

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 23, 2025, Structure Therapeutics Inc. (the "Company") held its 2025 Annual General Meeting of Shareholders (the "Annual General Meeting"). As of April 17, 2025, the record date for the Annual General Meeting, 172,610,249 ordinary shares were outstanding and entitled to vote at the Annual General Meeting. A summary of the matters voted upon by shareholders at the Annual General Meeting is set forth below.

*Proposal 1: Election of Directors*

Eric Dobmeier and Joanne Waldstreicher, M.D. were elected as Class II directors, to hold office until the 2028 Annual General Meeting of Shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of Director Elected** | **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| Eric Dobmeier | 133703367 | 596667 | 58398 | -0- |
| Joanne Waldstreicher, M.D. | 131397750 | 2896656 | 64026 | -0- |

---

*Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm*

The Company's shareholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 134291886 | 27066 | 39480 | -0- |

---

*Proposal 3: Advisory vote on the compensation of the Company's named executive officers*

On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual General Meeting. The voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 115026066 | 19231338 | 101028 | -0- |

---

*Proposal 4: Advisory vote on the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers*

The shareholders indicated, on an advisory basis, that the preferred frequency of the advisory vote on the compensation of the Company's named executive officers ("Say on Frequency") occur every year. The voting results were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1 Year** | **2 Years** | **3 Years** | **Abstentions** | **Broker Non-Votes** |
| 133649826 | 30855 | 97842 | 579909 | -0- |

---

Consistent with the recommendation of the Company's Board of Directors, as set forth in the Company's proxy statement for the Annual General Meeting, and based on the results of this non-binding advisory vote, it is the Company's intent that future advisory shareholder votes on the compensation of the Company's named executive officers will be held annually and included in the Company's proxy materials for each annual meeting until the next required vote on Say on Frequency.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Structure Therapeutics Inc.** | **Structure Therapeutics Inc.** |
| Date: June 25, 2025 | By: | /s/ Raymond Stevens |
|  |  | Raymond Stevens, Ph.D. |
|  |  | Chief Executive Officer |

---